Alterity Therapeutics Grants 3 Million In-The-Money Options to Chairman and Director
ATHE sits 81% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has granted 3 million in-the-money incentive options to its Chairman and a Director, which could lead to approximately 18.4% dilution for existing shareholders.
Key Events · Executive and Board Changes · ATHE
-
Chairman Receives Significant Option Grant
Julian Babarczy, Chairman, was granted 2,000,000 unlisted incentive options, exercisable at $1.00 per share and expiring on June 15, 2031.
-
Director Receives Option Grant
Lawrence Gozlan, a Director, was granted 1,000,000 unlisted incentive options, exercisable at $1.00 per share and expiring on June 15, 2031.
-
Substantial Potential Dilution
The total of 3,000,000 options granted represents approximately 18.4% potential dilution to existing shareholders if fully exercised.
-
In-The-Money Options
The options were granted with a strike price of $1.00, significantly below the current stock price of $4.81, making them immediately valuable.
Analysis · ATHE · Life Sciences
This filing confirms the actual grant of 3 million incentive options to the Chairman and a Director, following shareholder approval. These options, exercisable at $1.00, are significantly in-the-money relative to the current stock price of $4.81, representing substantial potential compensation. The grant introduces approximately 18.4% potential dilution to existing shareholders if all options are exercised.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 984 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.83%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.4M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.